Anurag Relan is a notable inventor based in Los Angeles, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of bleeding disorders. With a total of 3 patents, his work focuses on innovative solutions that enhance patient care.

Latest Patents

One of Anurag Relan's latest patents is for a pharmaceutical composition of recombinant human fibrinogen that has a half-life of less than 12 hours. This composition includes a pharmaceutically acceptable carrier or diluent and may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. Additionally, it may include divalent metal cations and sialic acid. Another patent involves a fibrinogen with reduced half-life and low sialic acid content, achieved through recombinant expression or enzymatic and chemical removal. This fibrinogen is particularly useful in treating or preventing bleeding in acute situations where a high initial dose and rapid decline to normal levels are desirable.

Career Highlights

Anurag Relan is currently employed at Laboratoire Francais Du Fractionnement Et Des Biotechnologies, where he continues to develop innovative pharmaceutical solutions. His expertise in recombinant technology and bleeding treatment has positioned him as a key player in the industry.

Collaborations

Anurag has collaborated with notable colleagues such as Frank Pieper and Erik Jordahl Forsberg, contributing to advancements in their shared field of expertise.

Conclusion

Anurag Relan's work in pharmaceutical innovation, particularly in the treatment of bleeding disorders, showcases his commitment to improving healthcare outcomes. His patents reflect a deep understanding of the complexities involved in developing effective treatments.

This text is generated by artificial intelligence and may not be accurate.